Document text
Principal Investigator: Matthew Hall
Organization: NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
Fiscal Year: 2022
Award: $4,088,041
Funding agency: National Center for Advancing Translational Sciences
During this past reporting period, NCATS continued development of a number of target-based SARS-CoV-2 assays to screen for potential hits against the virus. Optimized assays were screened against a panel of drug repurposing, clinical candidate and antiviral libraries that have been assembled at NCATS. These results have been made freely available to public with unprecedented speed through the NCATS OpenData Portal and through a number of preprint/journal publications.
These assays include both virus (e.g. Spike protein) and host (e.g. ACE2, TMPRSS) targets, as well as BSL3 live SARS-CoV-2 virus infectivity assays accessed through research contracts. Many assays have been solely developed in-house at NCATS, while a number of others have been designed in collaboration with both intramural and extramural laboratories with subject area expertise.
The COVID-19 pandemic is a pressing public health emergency garnering rapid response from scientists across the globe, and NCATS scientists have been conducting screening and drug repurposing against a number of SARS-CoV-2-related targets in response:
1) Host cell invasion is initiated through direct binding of the viral spike protein to the host receptor ACE2. Members of this team developed a proximity-based AlphaLISA assay to measure binding of SARS-CoV-2 spike RBD protein to ACE2 and used it to run a drug-repurposing screen, yielding 25 high-quality, small-molecule hits worthy of follow-up in cell-based models. This established AlphaLISA RBD-ACE2 platform allows scientists to evaluate disruption of this viral-host interaction, and this assay has been reported at multiple conferences.
2) The TMPRSS2 enzyme has been shown to be critically important for priming SARS-CoV-2 for viral entry into host cells, yet no SARS-CoV-2-related biochemical assay for this target had been previously reported. To enable inhibitor discovery and profiling of FDA-approved therapeutics, this team developed a biochemcial assay using recombinant TMPRSS2 suitable for high-throughput screening applications. The team validated this important assay, and demonstrated effectiveness to quantify inhibition down to subnanomolar concentrations using clinically approved proteases. This TMPRSS2 work will enable further screening against this important antiviral host target, and provide insight into selectivity and potency of repurposing candidates.
3) Antibodies that physically block viral entry of SARS-CoV-2 may provide leads for further therapeutic development. This project team used an innovative combination of humanized nanobody library and enrichment strategies (also known as phage panning) to discover several clones of antibodies capable of high-affinity binding to SARS-CoV-2 spike protein. Because these highly engineered antibody variants already incorporate beneficial features such as similarity to human antibodies, they are expected to be developed into viable therapeutic leads faster than other types of neutralizing antibodies.
4) Pulmonary fibrosis is a major problem associated with severe cases of SARS-CoV-2 infections and the leading cause of mortality associated with COVID-19. Currently, the only treatment is supplemental oxygen and mechanical ventilation to hospitalized COVID patients. There is no effective therapeutic measure to mitigate the disease. The goal of this project is to develop small molecular inhibitors as therapeutic measures to mitigate COVID-19 associated lung fibrosis.The project's goal is to develop small molecular inhibitors as therapeutic measures to mitigate COVID-19 associated lung fibrosis. During this period, we tried to optimize the absorbance-based assay developed in our collaborator's lab and develop fluorescence-based thrombin activity assay.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><ACE2><Active Follow-up><Address><Affinity><Antibodies><Area><Assay><Bacteriophages><Binding><Bioassay><Biochemical><Biologic Assays><Biological Assay><Biology><COVID associated pneumonia><COVID crisis><COVID epidemic><COVID induced pneumonia><COVID infected patient><COVID pandemic><COVID patient><COVID pneumonia><COVID positive patient><COVID related pneumonia><COVID-19><COVID-19 S protein><COVID-19 assay><COVID-19 associated pneumonia><COVID-19 crisis><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 induced pneumonia><COVID-19 infected patient><COVID-19 infection><COVID-19 pandemic><COVID-19 patient><COVID-19 pneumonia><COVID-19 positive patient><COVID-19 public health crisis><COVID-19 related pneumonia><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 therapeutics><COVID-19 virus><COVID19><COVID19 S protein><COVID19 assay><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 pandemic><COVID19 patient><COVID19 positive patient><COVID19 public health crisis><COVID19 spike glycoprotein><COVID19 spike protein><COVID19 therapeutics><COVID19 virus><CV-19><CV19><Cell Body><Cells><Clinical><CoV-2><CoV2><Collaborations><Communities><Data><Development><Disease><Disorder><Drugs><EXTMR><Effectiveness><Enzyme Gene><Enzymes><Epitheliasin Gene><Esteroproteases><Extramural><Extramural Activities><FDA approved><Fluorescence><Goals><High Throughput Assay><Human><Investigators><Journals><Laboratories><Libraries><Lung Tissue Fibrosis><Magazine><Measures><Mechanical ventilation><Medication><Modeling><Modern Man><Molecular Interaction><NCATS><National Center for Advancing Translational Sciences><PRSS10><Peptidases><Peptide Hydrolases><Phages><Pharmaceutic Preparations><Pharmaceutical Preparations><Position><Positioning Attribute><Protease Gene><Proteases><Proteinases><Proteins><Proteolytic Enzymes><Public Health><Publications><Pulmonary Fibrosis><Receptor Protein><Recombinants><Reporting><Research><Research Activity><Research Contracts><Research Personnel><Research Resources><Research Support><Researchers><Resources><Running><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 S protein><SARS-CoV-2 assay><SARS-CoV-2 associated pneumonia><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 induced pneumonia><SARS-CoV-2 infected patient><SARS-CoV-2 infection><SARS-CoV-2 pandemic><SARS-CoV-2 patient><SARS-CoV-2 pneumonia><SARS-CoV-2 positive patient><SARS-CoV-2 related pneumonia><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV-2 therapeutics><SARS-CoV2><SARS-CoV2 S protein><SARS-CoV2 epidemic><SARS-CoV2 infection><SARS-CoV2 pandemic><SARS-CoV2 spike glycoprotein><SARS-CoV2 spike protein><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 therapeutics><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Scientific Publication><Scientist><Screening Result><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome coronavirus 2 therapeutics><Severe acute respiratory syndrome related corona virus 2><Site><Societies><Speed><TMPRSS2><TMPRSS2 gene><Testing><Therapeutic><Therapeutic Intervention><Thrombase><Thrombin><Translational Research><Translational Science><Translations><Vaccines><Variant><Variation><Viral><Viral Diseases><Virus><Virus Diseases><Work><Wuhan coronavirus><active followup><angiotensin converting enzyme 2><angiotensin converting enzyme II><antibody engineering><assay development><atypical pneumonia><bacterial virus><base><beta CoV><beta coronavirus><betaCoV><betacoronavirus><block viral entry><clinical candidate><clinical efficacy><conference><convention><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><coronavirus disease 2019><coronavirus disease 2019 S protein><coronavirus disease 2019 assay><coronavirus disease 2019 associated pneumonia><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 induced pneumonia><coronavirus disease 2019 infected patient><coronavirus disease 2019 infection><coronavirus disease 2019 pandemic><coronavirus disease 2019 patient><coronavirus disease 2019 pneumonia><coronavirus disease 2019 positive patient><coronavirus disease 2019 public health crisis><coronavirus disease 2019 related pneumonia><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 therapeutics><coronavirus disease 2019 virus><coronavirus disease associated pneumonia><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease induced pneumonia><coronavirus disease infected patient><coronavirus disease pandemic><coronavirus disease patient><coronavirus disease pneumonia><coronavirus disease positive patient><coronavirus disease related pneumonia><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 patient><coronavirus disease-19 pneumonia><coronavirus disease-19 virus><coronavirus infectious disease-19><coronavirus patient><design><designing><developmental><drug repurposing><drug/agent><effective therapy><effective treatment><fibrinogenase><fibrosis in the lung><follow up><follow-up><followed up><followup><hCoV19><high throughput screening><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><inhibit viral entry><inhibitor><innovate><innovation><innovative><insight><intervention therapy><lung fibrosis><mechanical respiratory assist><mechanically ventilated><member><mortality><nCoV2><nanobodies><nanobody><neutralizing antibody><novel><pandemic><pandemic disease><patient infected with COVID><patient infected with COVID-19><patient infected with SARS-CoV-2><patient infected with coronavirus disease><patient infected with coronavirus disease 2019><patient infected with severe acute respiratory syndrome coronavirus 2><patient with COVID><patient with COVID-19><patient with COVID19><patient with SARS-CoV-2><patient with coronavirus disease><patient with coronavirus disease 2019><patient with severe acute respiratory distress syndrome coronavirus 2><pneumonia due to COVID><pneumonia due to COVID-19><pneumonia due to SARS-CoV-2><pneumonia due to coronavirus disease><pneumonia due to coronavirus disease 2019><pneumonia due to severe acute respiratory syndrome coronavirus 2><pneumonia in COVID><pneumonia in COVID-19><pneumonia in SARS-CoV-2><pneumonia in coronavirus disease><pneumonia in coronavirus disease 2019><pneumonia in severe acute respiratory syndrome coronavirus 2><public health emergency><receptor><repurposing agent><repurposing medication><response><screening><sdAb><severe acute respiratory syndrome coronavirus 2 assay><severe acute respiratory syndrome coronavirus 2 associated pneumonia><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 induced pneumonia><severe acute respiratory syndrome coronavirus 2 infected patient><severe acute respiratory syndrome coronavirus 2 patient><severe acute respiratory syndrome coronavirus 2 pneumonia><severe acute respiratory syndrome coronavirus 2 positive patient><severe acute respiratory syndrome coronavirus 2 related pneumonia><single domain antibodies><small molecular inhibitor><small molecule><summit><supplemental oxygen><symposia><symposium><therapeutic agent development><therapeutic development><therapeutically effective><therapeutics against COVID-19><therapeutics against COVID19><therapeutics against SARS-CoV-2><therapeutics against SARS-coronavirus-2><therapeutics against Severe acute respiratory syndrome coronavirus 2><therapeutics against coronavirus disease 2019><therapeutics for novel coronavirus><translation research><viral entry blocker><viral entry inhibitor><viral infection><virus infection><virus-induced disease><β CoV><β coronavirus><βCoV>